View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
June 29, 2018updated 27 Jul 2018 7:35am

M&As this week: Advent International, Eli Lilly

Advent International has entered an agreement to purchase Sanofi’s European generics business Zentiva for €1.9bn ($2.2bn).

Advent International has entered an agreement to purchase Sanofi’s European generics business Zentiva for €1.9bn ($2.2bn).

Advent intends to invest in Zentiva’s operations, production facilities and its research and development (R&D) pipeline, post transaction.

The acquisition will be closed in the fourth quarter of 2018, subject to customary closing conditions.

Based in the US, Advent International is a private equity firm, while Zentiva is a Czech Republic-based provider of generic medicines for various therapeutic areas.

The acquisition will enable the acquirer company to provide patients with high-quality treatments at lower cost.

“Eli Lilly has completed the acquisition of ARMO BioSciences for a cash consideration of more than $1.6bn.”

Eli Lilly has completed the acquisition of ARMO BioSciences for a cash consideration of more than $1.6bn.

The company signed an agreement to purchase all outstanding shares of ARMO at $50 a share in May this year.

Based in the US, Eli Lilly is a pharmaceutical company that provides drugs for cancer treatment, while ARMO, also based in the US, is an immuno-oncology firm that develops drug candidates to treat diseases related to immune system.

The acquisition of ARMO will be a complementary addition to Eli Lilly’s oncology portfolio.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU